Pro Share Advisors LLC Alnylam Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 7,586 shares of ALNY stock, worth $1.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,586
Previous 7,809 2.86%
Holding current value
$1.93 Million
Previous $1.9 Million 9.96%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$233.81 - $287.01 $52,139 - $64,003
-223 Reduced 2.86%
7,586 $2.09 Million
Q2 2024

Aug 13, 2024
SELL
$143.31 - $247.0 $145,889 - $251,446
-1,018 Reduced 11.53%
7,809 $1.9 Million
Q1 2024

May 08, 2024
BUY
$146.51 - $198.2 $118,526 - $160,343
809 Added 10.09%
8,827 $1.32 Million
Q4 2023

Feb 14, 2024
SELL
$151.41 - $196.57 $23,317 - $30,271
-154 Reduced 1.88%
8,018 $1.53 Million
Q3 2023

Nov 13, 2023
BUY
$170.77 - $211.65 $19,638 - $24,339
115 Added 1.43%
8,172 $1.45 Million
Q2 2023

Aug 10, 2023
SELL
$185.01 - $212.05 $140,052 - $160,521
-757 Reduced 8.59%
8,057 $1.53 Million
Q1 2023

May 11, 2023
SELL
$182.66 - $235.53 $589,443 - $760,055
-3,227 Reduced 26.8%
8,814 $1.77 Million
Q4 2022

Feb 02, 2023
BUY
$185.53 - $241.31 $6,122 - $7,963
33 Added 0.27%
12,041 $2.86 Million
Q3 2022

Nov 04, 2022
BUY
$138.54 - $232.0 $85,756 - $143,608
619 Added 5.44%
12,008 $2.4 Million
Q2 2022

Aug 01, 2022
SELL
$120.42 - $169.29 $457,716 - $643,471
-3,801 Reduced 25.02%
11,389 $1.66 Million
Q1 2022

May 10, 2022
SELL
$127.18 - $173.91 $592,150 - $809,724
-4,656 Reduced 23.46%
15,190 $2.48 Million
Q4 2021

Feb 08, 2022
SELL
$159.56 - $209.29 $1.33 Million - $1.75 Million
-8,361 Reduced 29.64%
19,846 $3.37 Million
Q3 2021

Nov 12, 2021
BUY
$169.75 - $207.73 $481,750 - $589,537
2,838 Added 11.19%
28,207 $5.33 Million
Q2 2021

Aug 13, 2021
BUY
$128.63 - $176.89 $898,223 - $1.24 Million
6,983 Added 37.98%
25,369 $4.3 Million
Q1 2021

May 14, 2021
SELL
$126.83 - $175.69 $206,859 - $286,550
-1,631 Reduced 8.15%
18,386 $2.6 Million
Q4 2020

Feb 09, 2021
SELL
$122.97 - $147.0 $83,250 - $99,519
-677 Reduced 3.27%
20,017 $2.6 Million
Q3 2020

Nov 13, 2020
BUY
$121.19 - $165.49 $63,261 - $86,385
522 Added 2.59%
20,694 $3.01 Million
Q2 2020

Aug 03, 2020
BUY
$104.21 - $156.44 $290,016 - $435,372
2,783 Added 16.0%
20,172 $2.99 Million
Q1 2020

May 15, 2020
SELL
$93.12 - $133.99 $874,024 - $1.26 Million
-9,386 Reduced 35.06%
17,389 $1.89 Million
Q4 2019

Feb 12, 2020
SELL
$74.51 - $124.23 $442,887 - $738,423
-5,944 Reduced 18.17%
26,775 $3.08 Million
Q3 2019

Nov 12, 2019
SELL
$70.9 - $87.82 $47,999 - $59,454
-677 Reduced 2.03%
32,719 $2.63 Million
Q2 2019

Aug 13, 2019
SELL
$65.86 - $92.79 $429,604 - $605,269
-6,523 Reduced 16.34%
33,396 $2.42 Million
Q1 2019

May 15, 2019
BUY
$72.76 - $93.45 $220,608 - $283,340
3,032 Added 8.22%
39,919 $3.73 Million
Q4 2018

Feb 14, 2019
SELL
$62.67 - $88.33 $459,183 - $647,193
-7,327 Reduced 16.57%
36,887 $2.69 Million
Q3 2018

Nov 14, 2018
SELL
$87.52 - $122.67 $1,662 - $2,330
-19 Reduced 0.04%
44,214 $3.87 Million
Q2 2018

Aug 13, 2018
SELL
$88.31 - $107.8 $356,065 - $434,649
-4,032 Reduced 8.35%
44,233 $4.36 Million
Q1 2018

May 14, 2018
SELL
$115.92 - $148.54 $853,750 - $1.09 Million
-7,365 Reduced 13.24%
48,265 $5.75 Million
Q4 2017

Feb 14, 2018
BUY
$114.49 - $139.98 $246,382 - $301,236
2,152 Added 4.02%
55,630 $7.07 Million
Q3 2017

Nov 13, 2017
BUY
$72.53 - $118.27 $360,691 - $588,156
4,973 Added 10.25%
53,478 $6.28 Million
Q2 2017

Aug 11, 2017
BUY
N/A
48,505
48,505 $3.87 Million

Others Institutions Holding ALNY

# of Institutions
644
Shares Held
109M
Call Options Held
1.28M
Put Options Held
1.21M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email